Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | JMJD6 | Q6NYC1 | 10/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224873 | 0.86 | CYP19A1 (0.45) | CYP19A1JMJD6KMT2ASCN4AKEAP1 | |
| SCHEMBL24378643 | 0.79 | KMT2A (0.51) | CYP19A1KMT2AMPOFGFR2FGFR3 | |
| SCHEMBL25606044 | 0.73 | KMT2A (0.56) | CYP19A1JMJD6KMT2ASCN4AKEAP1 | |
| SCHEMBL12299559 | 0.72 | KEAP1 (0.60) | CYP19A1KMT2ASCN4AKEAP1MAPT | |
| SCHEMBL16301333 | 0.72 | SMN1; SMN2 (0.38) | MAPT | |
| SCHEMBL10272781 | 0.71 | CYP19A1 (0.40) | CYP19A1JMJD6KMT2ASCN4AKEAP1 | |
| SCHEMBL321703 | 0.71 | NQO1 (0.50) | KMT2AMAPT | |
| SCHEMBL31510906 | 0.71 | KMT2A (0.52) | CYP19A1JMJD6KMT2ASCN4AKEAP1 | |
| SCHEMBL25610930 | 0.67 | JMJD6 (0.57) | CYP19A1JMJD6KMT2A | |
| SCHEMBL22041269 | 0.67 | KEAP1 (0.45) | CYP19A1JMJD6KMT2ASCN4AKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | CYP19A1 567/4885JMJD6 2753/4885KMT2A 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.